Salt Lake City, Utah
The 2024 Wilson Sonsini Entrepreneur and Investor Life Sciences Summit (E&I Summit), presented by BioUtah and the University of Utah Technology Licensing Office will feature an impressive line-up of distinguished speakers, national and local investors, and numerous Utah life sciences startups.
On Thursday, March 14th, from 8:45 am-9:30 a.m., Wilson Sonsini partner Nathan Robinson will moderate a CEO Panel with Ciara Kennedy, President & CEO of Sorriso Pharmaceuticals; Myles Greenberg, President & CEO of Alucent Biomedical, Inc.; Clark Turner, CEO of Turner Med Tech and Fred Lampropoulos, CEO of Merit Medical Systems.
On Thursday, March 14th, from 9:30 – 10:15 a.m., Wilson Sonsini partner, Marc Porter will moderate the panel, State of Venture Capital in Life Sciences with Adele Olivia, Founding Partner of 1315 Capital; Jenny Barba, Co-Founder, Managing Partner, of Features Capital; Nate Chang, Operating Partner, Life Sciences, Playground VC, and speaker Witney McKiernan, Principal of HealthQuest Capital.
Now in its 10th year, the E&I Summit convenes Utah’s life sciences leaders, entrepreneurs, and the investor community.
Norilyn Ingram
ningram@wsgr.comNathan Robinson is a partner in the Salt Lake City office of Wilson Sonsini Goodrich & Rosati, where he specializes in corporate and securities law, including general corporate representation, public offerings, private placements, and mergers and acquisitions. He has significant experience in counseling publicly held companies on disclosure matters and complex securities laws issues. He regularly works with emerging growth, technology, and life sciences companies, both public and private, as well as investment banks, venture capital funds, and private equity firms.
Marc Porter is a corporate partner in the Salt Lake City office of Wilson Sonsini Goodrich & Rosati, where his practice focuses on the representation of emerging technology, consumer product and life science companies, and the venture capital firms that fund them, in Utah and beyond. He executes a substantial volume of financings and liquidity events each year for early- to late-stage private companies as well as venture capital firms. Marc is a trusted advisor to executives, boards of directors, entrepreneurs and venture capital fund managers.